Trwa ładowanie...

Zaloguj

Notowania

SOPHARMA: strona spółki

20.03.2024, 15:29

SPH Sales revenues for February 2024

“Sopharma” AD (the Company) notifies that for February 2024 the Company recorded an decrease in sales of 29% compared to the same month of the previous year, incl. 9% decrease in domestic sales and 43% decrease in export sales.

Załączniki

Pobierz załącznik 1

Inne komunikaty

Data	Tytuł	Kurs	Zmiana
2024-04-25	SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format	13,05	0,00
2024-04-22	SPH Sales revenues of Sopharma AD for March 2024	13,70	0,00
2024-04-01	SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022	13,40	0,00
2024-03-20	SPH Sales revenues for February 2024	14,40	-3,13
2024-03-12	SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212	14,00	-1,43
2024-03-11	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase	13,80	+1,45
2024-02-29	SPH Consolidated financial report as of 31 December 2023	13,70	-2,19
2024-02-27	SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212	13,40	+2,99
2024-02-22	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants	13,75	-0,73
2024-02-22	SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the exercise of warrants in a capital increase under the condition	13,75	-0,73

Wszystke komunikaty